Trial Profile
A Randomized, Double-Blind (Sponsor Open), Placebo Controlled, Dose Escalating, Parallel Group, Multi-Centre Study To Investigate The Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous/Sub-Cutaneous Doses Of PF-00547659 In Patients With Active Ulcerative Colitis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ontamalimab (Primary) ; Ontamalimab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
- 11 Feb 2011 Results published in Gut.
- 09 Dec 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 24 Oct 2009 New trial record.